PMID- 26447714
OWN - NLM
STAT- MEDLINE
DCOM- 20160908
LR  - 20151121
IS  - 1423-0356 (Electronic)
IS  - 0025-7931 (Linking)
VI  - 90
IP  - 5
DP  - 2015
TI  - Disease-Targeted Treatment Improves Cognitive Function in Patients with 
      Precapillary Pulmonary Hypertension.
PG  - 376-83
LID - 10.1159/000439227 [doi]
AB  - BACKGROUND: Patients with pulmonary hypertension (PH) may suffer from cognitive 
      deficits that potentially relate to reduced oxygen delivery and cerebral tissue 
      oxygenation (CTO). OBJECTIVE: To evaluate the hypothesis that cognitive function 
      improves with therapy, along with improved CTO. METHODS: Twenty incident patients 
      with arterial or chronic thromboembolic PH had CTO monitoring by near-infrared 
      spectroscopy during diagnostic right heart catheterization. Cognitive tests 
      [Trail Making Tests (TMTs), Victoria Stroop tests and the Five-Point Test (5PT)], 
      the 6-min walk distance (6MWD) test, New York Heart Association (NYHA) class and 
      health-related quality of life (HRQoL) were assessed and repeated after 3 months 
      of disease-targeted medication. RESULTS: At baseline, 45% of PH patients had 
      cognitive deficits. At 3 months, the patients had improved on the TMT A and the 
      Stroop 2 test [37 s (27; 55) versus 30 s (24; 42), p < 0.05, and 18 s (16; 22) 
      versus 16 s (15; 20), p < 0.01], whereas CTO remained unchanged. Arterial oxygen 
      saturation, NYHA class, 6MWD and HRQoL had also improved. Baseline CTO was the 
      strongest predictor of cognitive function, even in multivariate analysis 
      including age, 6MWD and HRQoL. Improvements in cognitive function were not 
      associated with changes in CTO. CONCLUSIONS: In patients with PH, 3 months of 
      disease-targeted medication resulted in better cognitive function. Although CTO 
      was the strongest predictor of cognitive function at baseline, it did not change 
      during target therapy. The results of this pilot study should be confirmed in an 
      adequately powered controlled trial.
CI  - (c) 2015 S. Karger AG, Basel.
FAU - Somaini, Gina
AU  - Somaini G
AD  - Pulmonology Clinic, University Hospital Zurich, Zurich, Switzerland.
FAU - Stamm, Adriana
AU  - Stamm A
FAU - Muller-Mottet, Severine
AU  - Muller-Mottet S
FAU - Hasler, Elisabeth
AU  - Hasler E
FAU - Keusch, Stephan
AU  - Keusch S
FAU - Hildenbrand, Florian F
AU  - Hildenbrand FF
FAU - Furian, Michael
AU  - Furian M
FAU - Speich, Rudolf
AU  - Speich R
FAU - Bloch, Konrad E
AU  - Bloch KE
FAU - Ulrich, Silvia
AU  - Ulrich S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151009
PL  - Switzerland
TA  - Respiration
JT  - Respiration; international review of thoracic diseases
JID - 0137356
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Vasodilator Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analysis of Variance
MH  - Antihypertensive Agents/*administration & dosage
MH  - Capillaries/pathology
MH  - Cardiac Catheterization
MH  - Cognition/drug effects/physiology
MH  - Cohort Studies
MH  - Drug Delivery Systems/*methods
MH  - Exercise Tolerance/drug effects/physiology
MH  - Female
MH  - Humans
MH  - Hypertension, Pulmonary/*diagnosis/*drug therapy/mortality
MH  - Hypoxia-Ischemia, Brain/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Pilot Projects
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Pulmonary Circulation/*drug effects
MH  - *Quality of Life
MH  - Regression Analysis
MH  - Severity of Illness Index
MH  - Spectroscopy, Near-Infrared/methods
MH  - Switzerland
MH  - Vasodilator Agents/administration & dosage
EDAT- 2015/10/09 06:00
MHDA- 2016/09/09 06:00
CRDT- 2015/10/09 06:00
PHST- 2015/03/17 00:00 [received]
PHST- 2015/07/24 00:00 [accepted]
PHST- 2015/10/09 06:00 [entrez]
PHST- 2015/10/09 06:00 [pubmed]
PHST- 2016/09/09 06:00 [medline]
AID - 000439227 [pii]
AID - 10.1159/000439227 [doi]
PST - ppublish
SO  - Respiration. 2015;90(5):376-83. doi: 10.1159/000439227. Epub 2015 Oct 9.